SOPHiA GENETICS SA (SOPH) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-14

Key Insights

The reporting person, Daan van Well, who is the Chief Legal Officer of SOPHiA GENETICS SA, sold 2,400 ordinary shares in the open market on April 10, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units.
The shares were sold at a weighted average price of $4.6672, with the sales being executed pursuant to a pre-established Rule 10b5-1(c) trading plan.
Following the reported transaction, the reporting person continues to hold 346,420 ordinary shares of the issuer, indicating that the sale was likely for tax purposes and not a significant reduction in his overall ownership position.

Want the newest filings?

This analysis covers the filing from 2026-04-14. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-04-14

Insider Zhenyu Xu sold 8,120 shares of SOPHiA GENETICS SA (SOPH) on April 10 and 13, 2026 to satisfy tax withholding obligations from vesting of restricted stock units.
The sales were made pursuant to a pre-established 10b5-1 trading plan, indicating planned and non-discretionary transactions.
The share sales represent only a small portion (1.3%) of Xu's overall beneficial ownership, which remains at over 632,000 shares.

Filed: 2026-04-14

Jurgi Camblong, the CEO and a director of SOPHiA GENETICS SA, has sold a total of 16,631 ordinary shares on April 10 and April 13, 2026, pursuant to a pre-established 10b5-1 trading plan.
The sales were made to satisfy tax withholding obligations arising from the vesting of restricted stock units, and not for discretionary reasons.
The CEO still maintains a significant direct ownership of 3,707,569 ordinary shares, demonstrating his continued commitment to the company.

Filed: 2026-04-14

The reporting person, Ross Muken, who is the President of SOPHiA GENETICS SA, sold 3,687 ordinary shares on April 10, 2026 and 4,442 ordinary shares on April 13, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units.
The share sales were made pursuant to a pre-established Rule 10b5-1 trading plan, indicating they were non-discretionary and part of a systematic selling program.
After the reported transactions, the reporting person still holds a substantial position of 685,232 ordinary shares, suggesting continued confidence in the company.

Filed: 2026-04-14

The reporting person, Philippe Menu, who is the Chief Medical Officer of SOPHiA GENETICS SA (SOPH), has sold a total of 8,125 ordinary shares of the company in open market transactions on April 10th and 13th, 2026.
The share sales were made to satisfy tax withholding obligations arising from the vesting of restricted stock units, and were executed pursuant to a pre-established Rule 10b5-1(c) trading plan.
Following the reported transactions, the reporting person now beneficially owns 268,596 ordinary shares of SOPHiA GENETICS, indicating a decrease in his ownership stake.

Filed: 2026-04-10

Manuela Valente, the Chief People Officer of SOPHiA GENETICS SA, sold 3,824 ordinary shares in the open market on April 8, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units.
The sale was executed pursuant to a pre-established Rule 10b5-1 trading plan, indicating the transaction was non-discretionary and part of a predetermined selling strategy.
Valente still holds 215,451 ordinary shares directly, suggesting she maintains a significant equity stake in the company.

Filed: 2026-04-10

CEO Jurgi Camblong sold 4,750 ordinary shares of SOPHiA GENETICS SA (SOPH) on April 8-9, 2026 to satisfy tax withholding obligations related to the vesting of restricted stock units.
The shares were sold at weighted average prices of $4.84 and $4.74, respectively, pursuant to a pre-established 10b5-1 trading plan.
Camblong still holds 3,724,200 ordinary shares, representing a significant ownership stake as CEO and co-founder of the company.

Filed: 2026-04-10

The SEC Form 4 filing indicates that SOPHiA GENETICS SA's President, Ross Muken, sold a total of 4,736 ordinary shares over two days to satisfy tax withholding obligations related to the vesting of restricted stock units.
The share sales were executed pursuant to a pre-established Rule 10b5-1 trading plan, suggesting the transactions were non-discretionary and part of a predetermined plan.
The reported weighted average sale prices of $4.8414 and $4.7379 per share suggest the insider transactions occurred at market prices.

Filed: 2026-04-10

Insider Zhenyu Xu, the Chief Scientific Officer, sold 4,736 shares of SOPHiA GENETICS SA (SOPH) on April 8-9, 2026 to satisfy tax withholding obligations related to the vesting of restricted stock units.
The sales were executed pursuant to a pre-established Rule 10b5-1 trading plan, indicating the transactions were non-discretionary and pre-planned.
After the reported transactions, Xu still holds 640,216 shares, maintaining a significant ownership stake in the company.

Filed: 2026-04-10

The reporting person, Philippe Menu, who is the Chief Medical Officer of SOPHiA GENETICS SA, sold 4,731 ordinary shares of the company on April 8 and 9, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units.
The sales were executed pursuant to a pre-established Rule 10b5-1 trading plan, indicating they were non-discretionary and not based on any inside information.
The reported transactions do not indicate any significant change in the reporting person's overall beneficial ownership, which remains at 276,721 ordinary shares.

Filed: 2026-04-10

The reporting person, Daan van Well, who is the Chief Legal Officer of SOPHiA GENETICS SA, sold a total of 4,849 ordinary shares of the company on April 8 and April 9, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units.
The sales were executed pursuant to a pre-established Rule 10b5-1 trading plan, indicating that the transactions were non-discretionary and not based on any material non-public information.
The reporting person still holds 348,820 ordinary shares of the company, suggesting that he continues to maintain a significant ownership stake despite the recent sales.

Filed: 2026-04-10

Insider George Cardoza, the Chief Financial Officer, sold 1,403 ordinary shares of SOPHiA GENETICS SA (SOPH) to satisfy tax withholding obligations related to the vesting of restricted stock units.
The sale was executed pursuant to a pre-established Rule 10b5-1 trading plan, indicating the transaction was non-discretionary and not a reflection of Cardoza's market outlook.
The sale price was a weighted average of $4.8472, which is within the reported range of $4.79 to $4.93 per share.

Filed: 2026-04-08

Abhimanyu Verma, the Chief Technology Officer of SOPHiA GENETICS SA, has sold 3,549 ordinary shares in the company, likely to satisfy tax withholding obligations related to the vesting of restricted stock units.
The sales were executed pursuant to a pre-established Rule 10b5-1 trading plan, indicating the transactions were non-discretionary and not driven by insider trading concerns.
The volume of shares sold represents a small fraction of Verma's total beneficial ownership of 204,400 ordinary shares, suggesting his confidence in the company's long-term prospects.

Filed: 2026-04-08

The reporting person, Daan van Well, sold a total of 5,105 ordinary shares of SOPHiA GENETICS SA (SOPH) on April 6 and 7, 2026, likely to satisfy tax withholding obligations arising from the vesting of restricted stock units.
The sales were executed pursuant to a pre-established Rule 10b5-1 trading plan, indicating they were non-discretionary and not based on inside information.
The reporting person still beneficially owns 353,669 ordinary shares of SOPH, suggesting he maintains a significant stake in the company.

Filed: 2026-04-08

The reporting person, Ross Muken, sold 5,024 ordinary shares of SOPHiA GENETICS SA on April 6 and 7, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units. These sales were made pursuant to a pre-established 10b5-1 trading plan.
The selling price for the ordinary shares ranged from $4.6150 to $4.98 per share, with weighted average prices of $4.8474 and $4.8686 on the respective transaction dates.
Following the reported transactions, the reporting person continues to beneficially own 698,097 ordinary shares of SOPHiA GENETICS SA, representing a significant ownership position in the company.

Filed: 2026-04-08

Jurgi Camblong, the CEO of SOPHiA GENETICS SA, sold 5,100 ordinary shares on April 6-7, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units.
The share sales were executed pursuant to a pre-established Rule 10b5-1 trading plan, indicating the transactions were non-discretionary and likely part of Camblong's regular portfolio management.
Camblong still maintains a substantial direct ownership of 3,728,950 ordinary shares, suggesting his alignment with long-term shareholder interests.

Filed: 2026-04-08

The Chief Financial Officer (CFO) of SOPHiA GENETICS SA, George Cardoza, has sold a total of 4,933 ordinary shares on April 6 and April 7, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units.
The sales were executed pursuant to a pre-established Rule 10b5-1 trading plan, indicating the transactions were non-discretionary and not based on insider knowledge.
The CFO still holds a significant position of 292,861 ordinary shares following the reported transactions, suggesting ongoing alignment with the company's long-term interests.

Filed: 2026-04-08

Insider Manuela Valente, the Chief People Officer, sold 4,973 shares of SOPHiA GENETICS SA (SOPH) in early April 2026 to satisfy tax withholding obligations from vesting of restricted stock units.
The sales were executed pursuant to a pre-established Rule 10b5-1 trading plan, indicating they were non-discretionary transactions.
The share sales represent a small portion (around 2%) of Valente's total beneficial ownership of 221,651 ordinary shares in the company.

Filed: 2026-04-08

The reporting person, Zhenyu Xu, who is the Chief Scientific Officer of SOPHiA GENETICS SA, sold 2,700 and 2,400 ordinary shares on April 6 and April 7, 2026, respectively, to satisfy tax withholding obligations arising from the vesting of restricted stock units.
The shares were sold pursuant to a pre-established Rule 10b5-1 trading plan, indicating the sales were not discretionary and were part of a predetermined plan.
The reporting person still holds a significant number of shares, 644,952, indicating continued alignment with the company's long-term success.

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.